CA2457162A1 - Electroprocessed fibrin-based matrices and tissues - Google Patents
Electroprocessed fibrin-based matrices and tissues Download PDFInfo
- Publication number
- CA2457162A1 CA2457162A1 CA002457162A CA2457162A CA2457162A1 CA 2457162 A1 CA2457162 A1 CA 2457162A1 CA 002457162 A CA002457162 A CA 002457162A CA 2457162 A CA2457162 A CA 2457162A CA 2457162 A1 CA2457162 A1 CA 2457162A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrin
- cells
- matrix
- electroprocessed
- fibrinogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims abstract description 468
- 108010073385 Fibrin Proteins 0.000 title claims abstract description 459
- 102000009123 Fibrin Human genes 0.000 title claims abstract description 459
- 229950003499 fibrin Drugs 0.000 title claims abstract description 458
- 210000004027 cell Anatomy 0.000 claims abstract description 259
- 210000001519 tissue Anatomy 0.000 claims abstract description 111
- 239000000758 substrate Substances 0.000 claims abstract description 46
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 32
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 31
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 31
- 239000011159 matrix material Substances 0.000 claims description 247
- 239000003814 drug Substances 0.000 claims description 62
- 229940079593 drug Drugs 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 25
- 239000003102 growth factor Substances 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 239000002659 electrodeposit Substances 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 3
- 230000008512 biological response Effects 0.000 claims description 2
- 230000023597 hemostasis Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 abstract description 31
- 230000015572 biosynthetic process Effects 0.000 abstract description 18
- 239000006285 cell suspension Substances 0.000 abstract description 6
- 238000002513 implantation Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 120
- 108010049003 Fibrinogen Proteins 0.000 description 112
- 102000008946 Fibrinogen Human genes 0.000 description 112
- 229940012952 fibrinogen Drugs 0.000 description 112
- 239000000243 solution Substances 0.000 description 93
- 108090000190 Thrombin Proteins 0.000 description 88
- 229960004072 thrombin Drugs 0.000 description 88
- 239000000463 material Substances 0.000 description 51
- 230000008569 process Effects 0.000 description 48
- 238000001523 electrospinning Methods 0.000 description 43
- 239000000835 fiber Substances 0.000 description 36
- 230000002792 vascular Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 102000008186 Collagen Human genes 0.000 description 20
- 108010035532 Collagen Proteins 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 229920001436 collagen Polymers 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- -1 but not limited to Chemical compound 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- 206010052428 Wound Diseases 0.000 description 16
- 239000000443 aerosol Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 14
- 210000002747 omentum Anatomy 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 229920000954 Polyglycolide Polymers 0.000 description 12
- 230000005684 electric field Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 12
- 229920000747 poly(lactic acid) Polymers 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- 238000004070 electrodeposition Methods 0.000 description 7
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 210000004116 schwann cell Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000002322 conducting polymer Substances 0.000 description 5
- 229920001940 conductive polymer Polymers 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000007933 dermal patch Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000002660 insulin-secreting cell Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000003757 neuroblast Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- 102000008076 Angiogenic Proteins Human genes 0.000 description 3
- 108010074415 Angiogenic Proteins Proteins 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 101150081880 FGF1 gene Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 229920001410 Microfiber Polymers 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001857 anti-mycotic effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 108010073651 fibrinmonomer Proteins 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000003658 microfiber Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 3
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108010027612 Batroxobin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 210000000648 angioblast Anatomy 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 210000001054 cardiac fibroblast Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006854 communication Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 239000003356 suture material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000002423 Octamer Transcription Factor-6 Human genes 0.000 description 1
- 108010068113 Octamer Transcription Factor-6 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001856 aerosol method Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000007590 electrostatic spraying Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 239000000246 fibrin derivative Substances 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 210000001511 glucagon-secreting cell Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000007819 multidimensional cell growth Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000008365 organ synthesis Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000002685 pancreatic polypeptide-secreting cell Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000767 polyaniline Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012758 reinforcing additive Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000002465 tibial artery Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/006—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor using an electrostatic field for applying the material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Botany (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65451700A | 2000-09-01 | 2000-09-01 | |
| US09/654,517 | 2000-09-01 | ||
| US24100800P | 2000-10-18 | 2000-10-18 | |
| US60/241,008 | 2000-10-18 | ||
| US09/714,255 | 2000-11-17 | ||
| US60/270,118 | 2001-02-22 | ||
| PCT/US2001/027409 WO2002018441A2 (en) | 2000-09-01 | 2001-09-04 | Electroprocessed fibrin-based matrices and tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2457162A1 true CA2457162A1 (en) | 2002-03-07 |
Family
ID=26933909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002457162A Abandoned CA2457162A1 (en) | 2000-09-01 | 2001-09-04 | Electroprocessed fibrin-based matrices and tissues |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20020042128A1 (enExample) |
| EP (1) | EP1315756A2 (enExample) |
| JP (1) | JP2004508305A (enExample) |
| AU (1) | AU2001288692A1 (enExample) |
| CA (1) | CA2457162A1 (enExample) |
| MX (1) | MXPA03001914A (enExample) |
| WO (1) | WO2002018441A2 (enExample) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US7033603B2 (en) * | 1999-08-06 | 2006-04-25 | Board Of Regents The University Of Texas | Drug releasing biodegradable fiber for delivery of therapeutics |
| US20040013715A1 (en) | 2001-09-12 | 2004-01-22 | Gary Wnek | Treatment for high pressure bleeding |
| CN1455659A (zh) * | 2000-09-12 | 2003-11-12 | 弗吉尼亚州立大学 | 高压出血的治疗 |
| WO2002032397A2 (en) * | 2000-10-18 | 2002-04-25 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
| EP1982735A1 (en) * | 2000-11-17 | 2008-10-22 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
| KR100549140B1 (ko) * | 2002-03-26 | 2006-02-03 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 일렉트로-브로운 방사법에 의한 초극세 나노섬유 웹제조방법 |
| US20030195611A1 (en) * | 2002-04-11 | 2003-10-16 | Greenhalgh Skott E. | Covering and method using electrospinning of very small fibers |
| US7579442B2 (en) | 2002-04-16 | 2009-08-25 | Ocugenics, LLC | Method for stromal corneal repair and refractive alteration |
| US20030228287A1 (en) * | 2002-06-07 | 2003-12-11 | Regents Of The University Of California | Maintenance of islet cells |
| EP1555957A4 (en) * | 2002-10-04 | 2010-11-24 | Nanomatrix Inc | SEALANT FOR SKIN AND OTHER FABRICS |
| FR2847819B1 (fr) * | 2002-12-03 | 2006-05-19 | Univ Cergy Pontoise | Procede de preparation d'un materiau conducteur a activite fibrinolytique implantable dans l'organisme |
| WO2004091370A2 (en) * | 2003-04-10 | 2004-10-28 | The Trustees Of Boston University | Method for stimulating angiogenesis and wound healing |
| US7704740B2 (en) * | 2003-11-05 | 2010-04-27 | Michigan State University | Nanofibrillar structure and applications including cell and tissue culture |
| EP1722834B1 (en) | 2003-12-22 | 2012-06-27 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring crosslinked protein backbone |
| US7842667B2 (en) | 2003-12-22 | 2010-11-30 | Regentis Biomaterials Ltd. | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| US7789930B2 (en) * | 2006-11-13 | 2010-09-07 | Research Triangle Institute | Particle filter system incorporating nanofibers |
| US7762801B2 (en) * | 2004-04-08 | 2010-07-27 | Research Triangle Institute | Electrospray/electrospinning apparatus and method |
| US7297305B2 (en) | 2004-04-08 | 2007-11-20 | Research Triangle Institute | Electrospinning in a controlled gaseous environment |
| US7134857B2 (en) * | 2004-04-08 | 2006-11-14 | Research Triangle Institute | Electrospinning of fibers using a rotatable spray head |
| US7592277B2 (en) * | 2005-05-17 | 2009-09-22 | Research Triangle Institute | Nanofiber mats and production methods thereof |
| NL1026076C2 (nl) | 2004-04-29 | 2005-11-01 | Univ Eindhoven Tech | Vormdeel vervaardigd door middel van elektro-spinnen en een werkwijze voor de vervaardiging daarvan evenals de toepassing van een dergelijk vormdeel. |
| US9566370B2 (en) * | 2004-12-23 | 2017-02-14 | Novus Scientific Ab | Mesh implant for use in reconstruction of soft tissue defects |
| US9717825B2 (en) | 2004-12-23 | 2017-08-01 | Novus Scientific Ab | Mesh implant for use in reconstruction of soft tissue defects |
| US8048446B2 (en) * | 2005-05-10 | 2011-11-01 | Drexel University | Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds |
| US20090075354A1 (en) * | 2005-06-07 | 2009-03-19 | The University Of Akron | Nanofiber structures for supporting biological materials |
| US8354258B2 (en) | 2005-12-14 | 2013-01-15 | The Invention Science Fund I, Llc | Diatom device |
| US8900865B2 (en) * | 2005-12-14 | 2014-12-02 | The Invention Science Fund I, Llc | Blood brain barrier device |
| US8682619B2 (en) | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US8278094B2 (en) * | 2005-12-14 | 2012-10-02 | The Invention Science Fund I, Llc | Bone semi-permeable device |
| US9061075B2 (en) * | 2005-12-14 | 2015-06-23 | The Invention Science Fund I, Llc | Bone delivery device |
| US7855062B2 (en) * | 2005-12-14 | 2010-12-21 | The Invention Science Fund I, Llc | Bone cell delivery device |
| US8367384B2 (en) * | 2005-12-14 | 2013-02-05 | The Invention Science Fund I, Llc | Bone semi-permeable device |
| US9005944B2 (en) * | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
| US8734823B2 (en) | 2005-12-14 | 2014-05-27 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US20100303881A1 (en) * | 2006-02-02 | 2010-12-02 | The John Hopkins University | Therapeutic Electrospun Fiber Compositions |
| US8865869B2 (en) * | 2006-03-20 | 2014-10-21 | Worcester Polytechnic Institute | Collagen and fibrin microthreads in a discrete thread model of in vitro ACL scaffold regeneration |
| ES2405945T3 (es) * | 2006-03-28 | 2013-06-04 | Lnk Chemsolutions, Llc. | Método de manufactura de apósitos hemostáticos fibrosos |
| KR100736840B1 (ko) * | 2006-04-26 | 2007-07-10 | 한국기계연구원 | 3차원 조직 재생물 제조 장치 및 그를 이용한 제조 방법 |
| US8778380B2 (en) | 2006-04-26 | 2014-07-15 | Intellectual Discovery Co., Ltd. | Apparatus for fabricating 3D scaffold for inserting in a body to regenerate tissue |
| EP2656832B1 (en) | 2006-05-11 | 2018-12-19 | Regenics AS | Compositions for use in wound healing |
| US8557295B2 (en) | 2006-05-11 | 2013-10-15 | Regenics As | Use of cellular extracts for skin rejuvenation |
| EP2022276A4 (en) | 2006-05-18 | 2012-06-13 | Gustavo Larsen | METHOD FOR PRODUCING A MULTICOMPONENT BLOOD-HOLDING ASSOCIATION |
| US8083755B2 (en) | 2006-06-22 | 2011-12-27 | Novus Scientific Pte. Ltd. | Mesh implant for use in reconstruction of soft tissue defects |
| EP2061873B1 (en) * | 2006-09-21 | 2011-11-23 | Tissue Genesis | Cell delivery matrices |
| US8361365B2 (en) * | 2006-12-20 | 2013-01-29 | E I Du Pont De Nemours And Company | Process for electroblowing a multiple layered sheet |
| JP5973121B2 (ja) | 2007-01-30 | 2016-08-23 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 生体内分解性ラッピングおよびその使用 |
| AU2008211549B2 (en) | 2007-02-01 | 2012-12-06 | Abraham Katzir | Albumin fibers and fabrics and methods of generating and using same |
| US8790921B2 (en) | 2007-02-14 | 2014-07-29 | Drexel University | Alimentary protein-based scaffolds (APS) for wound healing, regenerative medicine and drug discovery |
| US8653632B2 (en) * | 2007-03-28 | 2014-02-18 | Medtronic Ats Medical Inc. | System and method for conditioning implantable medical devices |
| EP2129473B1 (en) * | 2007-03-28 | 2019-07-03 | Medtronic ATS Medical, Inc. | Method for inhibiting platelet interaction with biomaterial surfaces |
| WO2008137659A1 (en) * | 2007-05-04 | 2008-11-13 | University Of Virginia Patent Foundation | Compositions and methods for making and using laminin nanofibers |
| US8016841B2 (en) * | 2007-06-11 | 2011-09-13 | Novus Scientific Pte. Ltd. | Mesh implant with an interlocking knitted structure |
| EP2240090B1 (en) | 2008-01-25 | 2019-06-19 | The Johns Hopkins University | Biodegradable nerve guides |
| US20100040583A1 (en) * | 2008-03-27 | 2010-02-18 | Vincent Falanga | Compositions and methods using stem cells in cutaneous wound healing |
| MX338212B (es) * | 2008-04-11 | 2016-04-07 | Univ Virginia Commonwealth | Fibras de dextran electrohiladas y dispositivos formados de las mismas. |
| US10046081B2 (en) | 2008-04-11 | 2018-08-14 | The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. | Electrospun dextran fibers and devices formed therefrom |
| EP2296676B1 (en) | 2008-05-09 | 2016-11-02 | Regenics AS | Cellular extracts |
| US20110129510A1 (en) * | 2008-08-08 | 2011-06-02 | Basf Se | Fibrous surface structure containing active ingredients with controlled release of active ingredients, use thereof and method for the production thereof |
| WO2011005974A2 (en) * | 2009-07-08 | 2011-01-13 | Northwestern University | Interpenetrating biomaterial matrices and uses thereof |
| CA2778459C (en) | 2009-10-28 | 2016-08-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Bioerodible wraps and uses therefor |
| CA2784021C (en) | 2009-12-16 | 2018-03-20 | Neograft Technologies, Inc. | Graft devices and methods of use |
| US9295541B2 (en) | 2009-12-31 | 2016-03-29 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
| WO2011137270A1 (en) * | 2010-04-29 | 2011-11-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Cell and biofactor printable biopapers |
| US9090863B2 (en) | 2010-05-17 | 2015-07-28 | Pall Corporation | System for seeding cells onto three dimensional scaffolds |
| AU2010353739B2 (en) * | 2010-05-17 | 2014-03-27 | Pall Corporation | System for seeding cells onto three dimensional scaffolds |
| KR101703095B1 (ko) | 2010-06-17 | 2017-02-06 | 워싱톤 유니버시티 | 정렬된 섬유를 포함하는 생의학용 패치 |
| WO2012012407A2 (en) | 2010-07-19 | 2012-01-26 | Neograft Technologies, Inc. | Graft devices and methods of use |
| EP2659034B1 (en) | 2010-12-29 | 2019-02-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | System and method for mandrel-less electrospinning |
| EE05698B1 (et) | 2010-12-29 | 2014-02-17 | Tartu �likool | Meetod hemostaatilise bioadhesiivse v?rgustiku saamiseks |
| US10085829B2 (en) | 2011-01-14 | 2018-10-02 | Neograft Technologies, Inc. | Apparatus for creating graft devices |
| US9867690B2 (en) | 2011-02-09 | 2018-01-16 | Neograft Technologies, Inc. | System and mandrel for creating graft devices |
| US9126366B2 (en) | 2011-06-15 | 2015-09-08 | Korea Institute Of Machinery & Materials | Apparatus and method for manufacturing cell culture scaffold |
| US9579224B2 (en) | 2011-07-25 | 2017-02-28 | Neograft Technologies, Inc. | Vessel remodeling methods and devices for use in a graft device |
| WO2013090337A1 (en) | 2011-12-13 | 2013-06-20 | Neograft Technologies, Inc. | System and atraumatic mandrel for creating graft devices |
| DE102011122227A1 (de) * | 2011-12-23 | 2013-06-27 | Medizinische Hochschule Hannover | Verfahren und Vorrichtung zur Herstellung eines bioartifiziellen Gewebekonstrukts |
| SG11201502207WA (en) | 2012-09-21 | 2015-04-29 | Univ Washington | Biomedical patches with spatially arranged fibers |
| US11007385B2 (en) | 2012-12-10 | 2021-05-18 | Regenics As | Use of cellular extracts for skin rejuvenation |
| US9314549B2 (en) | 2013-04-24 | 2016-04-19 | University Of South Carolina | Bone tissue biomimetic materials |
| US10227566B2 (en) | 2013-10-30 | 2019-03-12 | University Of South Carolina | Three dimensional matrix for cancer stem cells |
| CN104027842B (zh) * | 2014-06-20 | 2016-06-08 | 东华大学 | 一种轴向取向纳米纤维神经导管的制备方法 |
| WO2016094106A1 (en) * | 2014-12-10 | 2016-06-16 | Cormatrix Cardiovascular, Inc. | Biocompatable annular prostheses and methods for forming same |
| US9238090B1 (en) * | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
| KR101733865B1 (ko) | 2015-06-26 | 2017-05-10 | 금오공과대학교 산학협력단 | 전기방사형 고분자 섬유를 포함하는 지혈재 및 그 제조방법 |
| CA3004734A1 (en) | 2015-11-12 | 2017-06-18 | St. Teresa Medical, Inc. | A method of sealing a durotomy |
| US10322206B2 (en) | 2016-03-29 | 2019-06-18 | Worcester Polytechnic Institute | Compositions and methods for wound healing |
| US10632228B2 (en) | 2016-05-12 | 2020-04-28 | Acera Surgical, Inc. | Tissue substitute materials and methods for tissue repair |
| WO2018071982A1 (en) * | 2016-10-20 | 2018-04-26 | Universal Biosensors Pty Ltd | Non-biohazardous solutions and methods for testing analysers |
| US10894019B2 (en) | 2017-08-15 | 2021-01-19 | University Of South Carolina | Drug delivery system and method for targeting cancer stem cells |
| WO2019089717A1 (en) | 2017-11-02 | 2019-05-09 | St. Teresa Medical, Inc. | Fibrin sealant products |
| CN108079373A (zh) * | 2018-01-22 | 2018-05-29 | 叶川 | 细胞支架材料的制备方法、材料及应用 |
| CN108096624A (zh) * | 2018-01-22 | 2018-06-01 | 叶川 | 细胞支架材料的制备方法、材料及应用 |
| WO2020203579A1 (ja) * | 2019-04-01 | 2020-10-08 | 凸版印刷株式会社 | 三次元組織体及びその製造方法並びに細胞含有組成物の製造方法 |
| US11672767B2 (en) | 2019-05-13 | 2023-06-13 | University Of South Carolina | Enzymatically cleavable self-assembled nanoparticles for morphogen delivery |
| EP4044964A4 (en) * | 2019-10-15 | 2023-11-08 | University of Cincinnati | Bioactive smart scaffolds for regenerative medicine |
| EP3929281A1 (en) | 2020-06-24 | 2021-12-29 | Fachhochschule Technikum Wien | Cell construct comprising schwann cells or schwann cell-like cells and a biocompatible matrix |
| JP7696492B2 (ja) | 2021-07-29 | 2025-06-20 | アセラ サージカル インコーポレイテッド | マクロ細孔およびミクロ細孔の複合ハイブリッドスケール繊維マトリクス |
| WO2023007443A2 (en) | 2021-07-29 | 2023-02-02 | Acera Surgical, Inc. | Particle-form hybrid-scale fiber matrix |
| WO2023039381A1 (en) | 2021-09-07 | 2023-03-16 | Acera Surgical, Inc. | Materials and methods for nerve repair and regeneration |
| IT202100025664A1 (it) * | 2021-10-07 | 2023-04-07 | Consiglio Nazionale Ricerche | Metodo per la fabbricazione di un patch medicale per il rilascio locale e controllato di sostanze bioattive per il trattamento di ulcere croniche, e patch medicale ottenuto con tale metodo |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975504A (en) | 1929-12-07 | 1934-10-02 | Richard Schreiber Gastell | Process and apparatus for preparing artificial threads |
| CA964131A (en) | 1971-03-01 | 1975-03-11 | Avicon | Microcrystalline collagen structures and method of preparing same |
| US3892648A (en) | 1974-04-16 | 1975-07-01 | Us Navy | Electrochemical deposition of bone |
| GB1527592A (en) | 1974-08-05 | 1978-10-04 | Ici Ltd | Wound dressing |
| EP0005035B1 (en) | 1978-04-19 | 1981-09-23 | Imperial Chemical Industries Plc | A method of preparing a tubular product by electrostatic spinning |
| JPS556061A (en) | 1978-06-29 | 1980-01-17 | Daiwa Kasei Kogyo Kk | Clamping tool for roddshaped member |
| JPS5569298A (en) | 1978-11-17 | 1980-05-24 | Kureha Chem Ind Co Ltd | Electrodeposition method of protein |
| US4323528A (en) | 1980-08-07 | 1982-04-06 | Valcour Imprinted Papers, Inc. | Method and apparatus for making large size, low density, elongated thermoplastic cellular bodies |
| DE3036814C2 (de) | 1980-09-30 | 1984-10-04 | Fa. Carl Freudenberg, 6940 Weinheim | Wundkompresse und Verfahren zu ihrer Herstellung |
| JPS5819331A (ja) | 1981-07-27 | 1983-02-04 | Kureha Chem Ind Co Ltd | 人工コラ−ゲン成形物およびその製法 |
| GB2121286B (en) | 1982-06-02 | 1985-11-06 | Ethicon Inc | Improvements in synthetic vascular grafts, and methods of manufacturing such grafts |
| US4552974A (en) * | 1982-12-07 | 1985-11-12 | Asahi Kasei Kogyo Kabushiki Kaisha | Process for producing diphenylmethane dicarbamates |
| GB2142870B (en) | 1983-07-06 | 1986-06-04 | Ethicon Inc | Manufacturing vascular prostheses by electrostatic spinning |
| US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4837285A (en) | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
| US4657793A (en) | 1984-07-16 | 1987-04-14 | Ethicon, Inc. | Fibrous structures |
| US4553974A (en) | 1984-08-14 | 1985-11-19 | Mayo Foundation | Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor |
| US4738740A (en) | 1985-11-21 | 1988-04-19 | Corvita Corporation | Method of forming implantable vascular grafts |
| GB8604328D0 (en) | 1986-02-21 | 1986-03-26 | Ici Plc | Producing spray of droplets of liquid |
| US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
| GB8614564D0 (en) | 1986-06-16 | 1986-07-23 | Ici Plc | Spraying |
| GB8614566D0 (en) | 1986-06-16 | 1986-07-23 | Ici Plc | Spraying |
| GB2195251A (en) | 1986-09-02 | 1988-04-07 | Ethicon Inc | Improvements in synthetic vascular grafts |
| US4837379A (en) * | 1988-06-02 | 1989-06-06 | Organogenesis Inc. | Fibrin-collagen tissue equivalents and methods for preparation thereof |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ES2109230T3 (es) | 1989-08-02 | 1998-01-16 | Univ North Carolina | Procedimiento para reticular materiales colaginosos y producto resultante. |
| GB8917916D0 (en) | 1989-08-04 | 1989-09-20 | Ethicon Inc | Improvements in synthetic vascular grafts and their methods of manufacture |
| US5256418A (en) | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
| US5378469A (en) | 1990-04-06 | 1995-01-03 | Organogenesis, Inc. | Collagen threads |
| US5292362A (en) | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| US5171505A (en) | 1990-11-28 | 1992-12-15 | E. I. Du Pont De Nemours And Company | Process for spinning polypeptide fibers |
| US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
| US5252285A (en) | 1992-01-27 | 1993-10-12 | E. I. Du Pont De Nemours And Company | Process for making silk fibroin fibers |
| US5326350A (en) | 1992-05-11 | 1994-07-05 | Li Shu Tung | Soft tissue closure systems |
| WO1994013266A1 (en) | 1992-05-29 | 1994-06-23 | The Regents Of The University Of California | Novel electrostatic process for manufacturing coated transplants and products |
| JPH06108307A (ja) | 1992-09-28 | 1994-04-19 | Mitsubishi Rayon Co Ltd | 高吸湿性繊維 |
| GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
| RU2034534C1 (ru) | 1992-12-22 | 1995-05-10 | Товарищество с ограниченной ответственностью - Научно-производственное предприятие "Экомедсервис" | Способ нанесения защитного асептического покрытия и устройство для его осуществления |
| US6105571A (en) | 1992-12-22 | 2000-08-22 | Electrosols, Ltd. | Dispensing device |
| JPH0797714A (ja) | 1993-05-06 | 1995-04-11 | Mitsubishi Rayon Co Ltd | コラーゲン繊維の製造法 |
| RU2031661C1 (ru) | 1993-07-16 | 1995-03-27 | Научно-производственное предприятие "Экомедсервис" | Средство для лечения ран и оказания первой медицинской помощи |
| US5460962A (en) | 1994-01-04 | 1995-10-24 | Organogenesis Inc. | Peracetic acid sterilization of collagen or collagenous tissue |
| GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| GB9406255D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| ATE219343T1 (de) | 1994-04-29 | 2002-07-15 | Scimed Life Systems Inc | Stent mit kollagen |
| GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
| GB9413029D0 (en) | 1994-06-29 | 1994-08-17 | Common Services Agency | Stem cell immobilisation |
| JPH0835193A (ja) | 1994-07-19 | 1996-02-06 | Mitsubishi Rayon Co Ltd | コラーゲン繊維不織シートの製造方法 |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5707962A (en) | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| US6057137A (en) | 1994-10-06 | 2000-05-02 | Regents Of The University Of Minnesota | Tissue-equivalent rods containing aligned collagen fibrils and schwann cells |
| US5948654A (en) | 1996-08-28 | 1999-09-07 | Univ Minnesota | Magnetically oriented tissue-equivalent and biopolymer tubes comprising collagen |
| JPH08143449A (ja) | 1994-11-17 | 1996-06-04 | Lederle Japan Ltd | 徐放性局所麻酔用注射剤 |
| US5648088A (en) * | 1995-03-06 | 1997-07-15 | Ethicon, Inc. | Blends of absorbable polyoxaesters containing amines and/or amide groups |
| US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
| US5674394A (en) | 1995-03-24 | 1997-10-07 | Johnson & Johnson Medical, Inc. | Single use system for preparation of autologous plasma |
| US6100026A (en) | 1995-04-25 | 2000-08-08 | Irori | Matrices with memories and uses thereof |
| US6121042A (en) | 1995-04-27 | 2000-09-19 | Advanced Tissue Sciences, Inc. | Apparatus and method for simulating in vivo conditions while seeding and culturing three-dimensional tissue constructs |
| US5830708A (en) | 1995-06-06 | 1998-11-03 | Advanced Tissue Sciences, Inc. | Methods for production of a naturally secreted extracellular matrix |
| US5908777A (en) | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| JP3554412B2 (ja) | 1995-08-07 | 2004-08-18 | 株式会社メニコン | 培養皮膚用基材、培養皮膚およびその製造法 |
| US5714359A (en) | 1995-10-12 | 1998-02-03 | The University Of Akron | Apparatus and method for electrostatic endothelial cell seeding in a vascular prosthesis |
| US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
| US6309661B1 (en) | 1996-02-28 | 2001-10-30 | Carla A. Haynes | Solid polysaccharide materials for use as wound dressings |
| US6252129B1 (en) | 1996-07-23 | 2001-06-26 | Electrosols, Ltd. | Dispensing device and method for forming material |
| US7193124B2 (en) | 1997-07-22 | 2007-03-20 | Battelle Memorial Institute | Method for forming material |
| AU3628497A (en) * | 1996-07-23 | 1998-02-10 | Electrosols Limited | A dispensing device and method for forming material |
| US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| CA2267449C (en) | 1996-11-05 | 2008-10-14 | Purdue Research Foundation | Myocardial graft constructs |
| US6433154B1 (en) * | 1997-06-12 | 2002-08-13 | Bristol-Myers Squibb Company | Functional receptor/kinase chimera in yeast cells |
| US6096309A (en) | 1997-06-18 | 2000-08-01 | Cohesion Technologies, Inc. | Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof |
| US6254627B1 (en) | 1997-09-23 | 2001-07-03 | Diseno Y Desarrollo Medico S.A. De C.V. | Non-thrombogenic stent jacket |
| US6106913A (en) | 1997-10-10 | 2000-08-22 | Quantum Group, Inc | Fibrous structures containing nanofibrils and other textile fibers |
| JP3596658B2 (ja) | 1997-11-12 | 2004-12-02 | 東洋紡績株式会社 | 培養細胞を用いた毒性評価方法 |
| US6179872B1 (en) | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
| ATE227338T1 (de) | 1998-03-18 | 2002-11-15 | Massachusetts Inst Technology | Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane |
| US6110590A (en) | 1998-04-15 | 2000-08-29 | The University Of Akron | Synthetically spun silk nanofibers and a process for making the same |
| US6103571A (en) * | 1998-04-30 | 2000-08-15 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for forming a DRAM capacitor having improved capacitance and device formed |
| US6265333B1 (en) | 1998-06-02 | 2001-07-24 | Board Of Regents, University Of Nebraska-Lincoln | Delamination resistant composites prepared by small diameter fiber reinforcement at ply interfaces |
| CN1105795C (zh) | 1998-06-11 | 2003-04-16 | 清水庆彦 | 胶原材料及其制造方法 |
| US20020022588A1 (en) | 1998-06-23 | 2002-02-21 | James Wilkie | Methods and compositions for sealing tissue leaks |
| US6245345B1 (en) | 1998-07-07 | 2001-06-12 | Atrix Laboratories, Inc. | Filamentous porous films and methods for producing the same |
| US6117296A (en) | 1998-07-21 | 2000-09-12 | Thomson; Timothy | Electrically controlled contractile polymer composite |
| US6190893B1 (en) | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
| US6146892A (en) | 1998-09-28 | 2000-11-14 | The Regents Of The University Of Michigan | Fibrillar matrices |
| ATE305967T1 (de) | 1998-11-19 | 2005-10-15 | Organogenesis Inc | Biotechnisch konstruiertes gewebe und verfahren zu dessen produktion und benutzung |
| US6110484A (en) | 1998-11-24 | 2000-08-29 | Cohesion Technologies, Inc. | Collagen-polymer matrices with differential biodegradability |
| KR100441126B1 (ko) * | 1999-01-11 | 2004-07-21 | 가네보 고센 가부시끼가이샤 | 스크린사(紗)용 폴리에스테르모노필라멘트 |
| JP3463596B2 (ja) | 1999-03-29 | 2003-11-05 | ニプロ株式会社 | 縫合可能な癒着防止膜 |
| WO2001015754A1 (en) | 1999-08-31 | 2001-03-08 | Virginia Commonwealth University Intellectual Property Foundation | Engineered muscle |
| US6364903B2 (en) | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
| US6548058B1 (en) * | 1999-07-20 | 2003-04-15 | Epitech, S.A. | Keratinocyte culture and uses thereof |
| US6103255A (en) | 1999-04-16 | 2000-08-15 | Rutgers, The State University | Porous polymer scaffolds for tissue engineering |
| GB9910505D0 (en) | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
| WO2000072857A1 (en) | 1999-06-01 | 2000-12-07 | Bristol-Myers Squibb Company | Fibrin polymer structure |
| US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
| AU8001000A (en) | 1999-10-08 | 2001-04-23 | University Of Akron, The | Electrospun skin masks and uses thereof |
| US6753454B1 (en) | 1999-10-08 | 2004-06-22 | The University Of Akron | Electrospun fibers and an apparatus therefor |
| US7264762B2 (en) | 2000-01-06 | 2007-09-04 | Drexel University | Electrospinning ultrafine conductive polymeric fibers |
| GB2360789A (en) * | 2000-03-30 | 2001-10-03 | Christopher Mason | Method of producing tissue structures |
| CA2405169C (en) | 2000-04-03 | 2011-07-26 | Battelle Memorial Institute | Devices and formulations |
| US20020084178A1 (en) | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
| US6641773B2 (en) | 2001-01-10 | 2003-11-04 | The United States Of America As Represented By The Secretary Of The Army | Electro spinning of submicron diameter polymer filaments |
-
2001
- 2001-09-04 AU AU2001288692A patent/AU2001288692A1/en not_active Abandoned
- 2001-09-04 CA CA002457162A patent/CA2457162A1/en not_active Abandoned
- 2001-09-04 JP JP2002523955A patent/JP2004508305A/ja active Pending
- 2001-09-04 EP EP01968446A patent/EP1315756A2/en not_active Withdrawn
- 2001-09-04 US US09/946,158 patent/US20020042128A1/en not_active Abandoned
- 2001-09-04 WO PCT/US2001/027409 patent/WO2002018441A2/en not_active Ceased
- 2001-09-04 MX MXPA03001914A patent/MXPA03001914A/es active IP Right Grant
-
2004
- 2004-01-26 US US10/764,691 patent/US7759082B2/en not_active Expired - Fee Related
-
2010
- 2010-06-08 US US12/796,207 patent/US20100310658A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1315756A2 (en) | 2003-06-04 |
| MXPA03001914A (es) | 2004-05-24 |
| JP2004508305A (ja) | 2004-03-18 |
| AU2001288692A1 (en) | 2002-03-13 |
| US20100310658A1 (en) | 2010-12-09 |
| WO2002018441A3 (en) | 2002-05-30 |
| US20020042128A1 (en) | 2002-04-11 |
| US7759082B2 (en) | 2010-07-20 |
| WO2002018441A2 (en) | 2002-03-07 |
| US20040229333A1 (en) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7759082B2 (en) | Electroprocessed fibrin-based matrices and tissues | |
| US7615373B2 (en) | Electroprocessed collagen and tissue engineering | |
| EP1345743B1 (en) | Electroprocessed collagen | |
| US7374774B2 (en) | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers | |
| US20020090725A1 (en) | Electroprocessed collagen | |
| JP4619789B2 (ja) | 皮膚およびその他の組織のためのシーラント | |
| AU6617300A (en) | Engineered muscle | |
| EP1333808B1 (en) | Electroprocessed composition used in drug delivery and cell encapsulation | |
| WO2003099230A2 (en) | Electroprocessed collagen and tissue engineering | |
| WO2009149181A2 (en) | Methods and compositions for manipulating electroprocessed scaffold material properties using cross-linking and fiber tertiary structure | |
| AU2002224387A1 (en) | Electroprocessing in drug delivery and cell encapsulation | |
| JP2010163435A (ja) | 電気処理されたコラーゲン | |
| AU2011203262A1 (en) | Electroprocessed fibrin-based matrices and tissues | |
| AU2007219278A1 (en) | Electroprocessed fibrin-based matrices and tissues | |
| AU2011204877A1 (en) | Electroprocessing in drug delivery and cell encapsulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |